{"version":"1.0","type":"link","title":"Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.","author_name":"Shadman M 외","author_url":"https://prs-insight.online/author/Shadman%20M","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/162291","thumbnail_width":1200,"thumbnail_height":630}